当UV1癌症疫苗遇到免疫检查点阻断：阳性免疫反应但阴性临床结果。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-07-11 DOI:10.1016/j.medj.2025.100664

Guo Zhao, Shuhang Wang, Ning Li

{"title":"当UV1癌症疫苗遇到免疫检查点阻断：阳性免疫反应但阴性临床结果。","authors":"Guo Zhao, Shuhang Wang, Ning Li","doi":"10.1016/j.medj.2025.100664","DOIUrl":null,"url":null,"abstract":"Brandt et al. present findings from the phase 2 FOCUS trial evaluating UV1 vaccine combined with pembrolizumab in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. While UV1 elicited human telomerase reverse transcriptase-specific T cell responses in 86% of patients, clinical outcomes showed no improvement over pembrolizumab monotherapy.1 This discordance between immune activation and therapeutic efficacy underscores the necessity for further disease understanding and vaccine design in the future.","PeriodicalId":29964,"journal":{"name":"Med","volume":"6 7","pages":"100664"},"PeriodicalIF":12.8000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"When UV1 cancer vaccine meets immune checkpoint blockade: Positive immune response but negative clinical outcome.\",\"authors\":\"Guo Zhao, Shuhang Wang, Ning Li\",\"doi\":\"10.1016/j.medj.2025.100664\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Brandt et al. present findings from the phase 2 FOCUS trial evaluating UV1 vaccine combined with pembrolizumab in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. While UV1 elicited human telomerase reverse transcriptase-specific T cell responses in 86% of patients, clinical outcomes showed no improvement over pembrolizumab monotherapy.1 This discordance between immune activation and therapeutic efficacy underscores the necessity for further disease understanding and vaccine design in the future.\",\"PeriodicalId\":29964,\"journal\":{\"name\":\"Med\",\"volume\":\"6 7\",\"pages\":\"100664\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2025.100664\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2025.100664","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

Brandt等人发表了2期FOCUS试验的研究结果，该试验评估了UV1疫苗联合派姆单抗治疗pd - l1阳性复发/转移性头颈部鳞状细胞癌。虽然UV1在86%的患者中引发了人类端粒酶逆转录特异性T细胞反应，但临床结果显示，与派姆单抗单药治疗相比，没有改善免疫激活和治疗效果之间的这种不一致强调了未来进一步了解疾病和设计疫苗的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

When UV1 cancer vaccine meets immune checkpoint blockade: Positive immune response but negative clinical outcome.

Brandt et al. present findings from the phase 2 FOCUS trial evaluating UV1 vaccine combined with pembrolizumab in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. While UV1 elicited human telomerase reverse transcriptase-specific T cell responses in 86% of patients, clinical outcomes showed no improvement over pembrolizumab monotherapy.¹ This discordance between immune activation and therapeutic efficacy underscores the necessity for further disease understanding and vaccine design in the future.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.